Search 

Enzymogen is a biotechnology company developing cannabinoids in algae as new drug entities.
Main activities:
Development of a platform for producing API cannabinoids based on proprietary technology (not plant extracts);
Develop cannabinoids as drugs for unmet clinical needs.

ExpressCells is genetic-engineering company that creates custom and catalog knock-in cell lines for biological research. Our approach uses CRISPR plus our patent-pending plasmid system that creates cell lines up to 75% faster than older technologies and allows multiple knock-ins. Our living cells replicate diseases or have proteins glow in multiple colors, speeding drug development. We are generating revenue through e-commerce, online promotion, and sales representatives.

Dry Eye Disease (DED) significantly impacts quality of life and vision, and the incidence is growing 7% annually (30M in US, 350M worldwide). Time spent on digital screens is accelerating this increase. There is currently no cure, and available treatments often create fear, anxiety, and discomfort, and are costly. Eyedetec Medical is developing a novel, internet connected, non-invasive platform medical device for treating patients that is effective, soothing, and relaxing, and will be used by patients in office and at home. The scalability and flexibility of this approach enables doctors to meet growing patient demand while generating meaningful new revenue. Proof-of-concept clinical data is positive. This novel therapy is easier to use, much more comfortable for the patient, and significantly less expensive than alternatives.

GattaCo develops products that enable fast accurate evidence-based decision making to improve healthcare outcomes. We do this by solving the fundamental problems in sample purification, the most challenging component of the diagnostic testing workflow.

 Our new Plasm™ Module is a revolutionary, patented, automatic plasma separation and metering module or insert used to provide high-purity, metered plasma to a rapid diagnostic testing platform, such as lateral flow, biosensor, or other Point of Care (POC) device, from finger-stick capillary blood. The initial version of the Plasm Module is optimized for antibody testing and will revolutionize POC diagnostics by improving: 

• Sensitivity: Increased number of antibodies compared to the same volume of whole blood.
• Specificity Accuracy: High quality/purity sample with reduced background.
• Repeatability: Plasma is metered to +/- 5%.
Quantitation: Precisely metered output, independent of hematocrit.